Stock comparison
Gilead Sciences
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GILD
Gilead Sciences
Market cap
$166.82B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GILD | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 60C | 75B | IDXX |
| Benjamin Graham | 73B | 80A | IDXX |
| Philip Fisher | 61C | 75B | IDXX |
| Peter Lynch | 55C | 71B | IDXX |
| Joel Greenblatt | 47D | 83C | IDXX |
| Charlie Munger | 74C | 87A | IDXX |
| Terry Smith | 71B | 84A | IDXX |
Side-by-side metrics
| Metric | GILD | IDXX |
|---|---|---|
| Market cap | $166.82B | $44.12B |
| P/E (TTM) | 17.5x | 39.0x |
| EV/EBIT | 15.0x | 31.6x |
| ROIC (TTM) | 20.31% | 40.66% |
| Gross margin | 79.35% | 62.05% |
| Net margin | 30.99% | 24.63% |
| Revenue CAGR 5y | 1.9% | 7.56% |
| EPS CAGR 5y | 8.37% | 10.79% |
| Debt / Equity | 0.9x | 0.7x |
| Dividend yield | 2.46% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GILD leads on
- Dividend yield2.46%vs 0.0%+100%
- Market cap$166.82Bvs $44.12B+74%
- P/E (TTM)17.5xvs 39.0x+55%
- EV/EBIT15.0xvs 31.6x+53%
IDXX leads on
- Revenue CAGR 5y7.56%vs 1.9%+75%
- ROIC (TTM)40.66%vs 20.31%+50%
- Debt / Equity0.7xvs 0.9x+26%
- EPS CAGR 5y10.79%vs 8.37%+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.